Thera-SAbDab

IPILIMUMAB

>   Structural Summary
TherapeuticIpilimumab
TargetCTLA4/CD152
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFTFSSYTMHWVRQAPGKGLEWVTFISYDGNNKYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAIYYCARTGWLGPFDYWGQGTLVTVSS
Light ChainEIVLTQSPGTLSLSPGERATLSCRASQSVGSSYLAWYQQKPGQAPRLLIYGAFSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQYGSSPWTFGQGTKVEIK
100% seqID Fv Structure5tru [Fvs: HL, hl], 5xj3 [Fvs: AB, DE, GH, JK], 6jc2 [Fvs: HL], 6rp8 [Fvs: HL, hl], 7elx [Fvs: HL]
99% seqID Fv StructureNone
95-98% seqID Fv Structure7su0 [Fvs: HL, IM], 7su1 [Fvs: HL]
>   Alignments

Non-identical sequences have been numbered using the Chothia scheme and aligned to Ipilimumab.
CDR positions are indicated in blue. Mismatching positions are highlighted in orange.

Sequence identity: 97.79%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
ipilimumab Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y T M H W V R Q A P G K G L E W V T F I S Y D G N N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R T G W L G P F D Y W G Q G T L V T V S S
7su0 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S H Y T M H W V R Q A P G K G L E W V T F I S Y D G H N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R T G W L G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ipilimumab E I V L T Q S P G T L S L S P G E R A T L S C R A S Q S V G S S Y L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
7su0 E I V L T Q S P G T L S L S P G E R A T L S C R A S Q E V G E S E L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
Sequence identity: 97.35%

Heavy chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 52A 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 82A 82B 82C 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 100A 101 102 103 104 105 106 107 108 109 110 111 112 113
ipilimumab Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S S Y T M H W V R Q A P G K G L E W V T F I S Y D G N N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R T G W L G P F D Y W G Q G T L V T V S S
7su1 Q V Q L V E S G G G V V Q P G R S L R L S C A A S G F T F S H Y T M H W V R Q A P G K G L E W V T F I S Y D G H N K Y Y A D S V K G R F T I S R D N S K N T L Y L Q M N S L R A E D T A I Y Y C A R H G W L G P F D Y W G Q G T L V T V S S

Light chain

Position 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 30A 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 100 101 102 103 104 105 106 107
ipilimumab E I V L T Q S P G T L S L S P G E R A T L S C R A S Q S V G S S Y L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
7su1 E I V L T Q S P G T L S L S P G E R A T L S C R A S Q E V G E S E L A W Y Q Q K P G Q A P R L L I Y G A F S R A T G I P D R F S G S G S G T D F T L T I S R L E P E D F A V Y Y C Q Q Y G S S P W T F G Q G T K V E I K
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (Aug '24)Approved
Estimated Status (Aug '24)Active
Recorded Developmental TechnologyMedarex UltiMAb Mouse
INN Year Proposed2005
INN Year Recommended2006
Companies InvolvedAduro BioTech, AIO Studien gGmbH, Australian and New Zealand Urogenital and Prostate Cancer Group, Bavarian Nordic, Big Ten Cancer Research Consortium, BioGene Pharmaceutical, Bristol-Myers Squibb, Canadian Cancer Trials Group, Dana-Farber Cancer Institute, European Thoracic Oncology Platform, Grupo Espanol Multidisciplinar de Melanoma, Icahn School of Medicine at Mount Sinai, Intergroupe Francophone de Cancerologie Thoracique, Ludwig Institute for Cancer Research, Massachusetts General Hospital, Medarex, Memorial Sloan-Kettering Cancer Center, National Cancer Institute (USA), National University Hospital (Singapore), Northwestern University, Olivia Newton-John Cancer Research Institute, OncoTherapy Science, Ono Pharmaceutical, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, University College London, University of California at San Francisco, University of Texas M. D. Anderson Cancer Center
Conditions ApprovedMalignant melanoma, Renal cell carcinoma
Conditions ActiveColorectal cancer, Non-small cell lung cancer, Gastric cancer, Glioblastoma, Head and neck cancer, Mesothelioma, Oesophageal cancer, Prostate cancer, Small cell lung cancer, Urogenital cancer, Adrenocortical carcinoma, Breast cancer, CNS cancer, Gastrointestinal cancer, Genitourinary disorders, Gynaecological cancer, Liver metastases, Meningeal carcinomatosis, Myelodysplastic syndromes, Neuroendocrine tumours, Ovarian cancer, Pancreatic cancer, Penile cancer, Solid tumours, Thyroid cancer, Uveal melanoma, Diffuse large B cell lymphoma, Liver cancer, Lung cancer, Glioma
Conditions DiscontinuedHIV infections, Lymphoma
NotesBiosimilars available

Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]

Our privacy policy